Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis.
Mah I Kan ChangezMaimoona KhanMuhammad UzairMuhammad Fawad TahirMaryam MohsinAmna Faiyaz HussainVania SaqibMuhammad Khizer MolaniAisha Habib AhmedSaad KhalidPublished in: Journal of gastrointestinal cancer (2023)
Our study concluded that combination therapy with atezolizumab plus bevacizumab could increase the survival duration without affecting the disease course. Moreover, while the severity of adverse events was greater in the A + B group, their frequency was comparable to the lenvatinib group.